The US Department of Health convened an “emergency meeting” to discuss an unexpected number of reports of heart infections following mRNA vaccinations. Young men in particular were affected. Despite this, at least one pharmaceutical giants is now planning to test vaccines on six-month-old children.
These infections were noted from Pfizer and Modernavaccinations. The US Centers for Disease Control and Prevention (CDC) announced on Thursday that they would call an “emergency meeting” of their advisors on June 18 to deal with the unexpectedly high number of heart inflammation reports following the administration of mRNA-based vaccines.
New details about myocarditis and pericarditis first surfaced in presentations to a panel of independent Food and Drug Administration (FDA) advisors that met this week to discuss an emergency approval for Covid-19 vaccines for toddlers.
According to a report by the US news broadcaster CBS, the CDC had previously announced that reports of heart infections had occurred especially in younger men and teenage boys after the second dose of vaccine, and that 16- to 24-year-olds had “a higher number of observed Cases than expected”. Last month, the CDC asked doctors to “ask about a previous Covid-19 vaccination” in patients with symptoms of heart inflammation.
According to a report by US online news site The Epoch Times, the US government has received nearly 800 reports of heart infections in people who received a Covid-19 vaccine. The CDC said they were currently investigating 226 of the nearly 800 reports.
Meanwhile, the US Children’s Health Defense Fund reported that Pfizer announced earlier this week that it had decided on doses to be used in a clinical trial in children six months of age; the group hopes to be able to present data by October. Pfizer previously received emergency approval for its vaccine against Covid-19 for children aged twelve last month. Moderna stated that it had also applied for FDA permission to give its mRNA vaccine to teenagers.
While Pfizer has announced that it will complete the trials for children ages two and up by September, FDA officials had previously warned that vaccine approval for these age groups could take longer – “mid to late autumn” at the earliest. In doing so, they relied on the additional follow-up data required for children after vaccination.
In Germany, The Standing Vaccination Commission (STIKO) has warned that vaccination for children without previous illnesses is currently not generally recommended.